Categories
Change Password!
Reset Password!
A 24-week randomized controlled trial was performed to investigate gingivitis and the percentage of individuals moving between gingivitis severity (< 10, > 10 < 30, > 30% bleeding sites), and plaque decline, after twice-daily usage of an experimental non-aqueous stannous fluoride dentifrice (0.454% weight/weight), vs. a negative control dentifrice over 12 and 24 weeks.
A dentifrice containing 0.454% weight/weight stannous
fluoride displayed superiority to a standard dentifrice to manage
supra-gingival plaque and gingivitis, over 24-weeks.
A 24-week randomized controlled
trial was performed to investigate gingivitis and the percentage of individuals
moving between gingivitis severity (< 10, > 10 < 30, > 30% bleeding
sites), and plaque decline, after twice-daily usage of an experimental
non-aqueous stannous fluoride dentifrice (0.454% weight/weight), vs. a negative
control dentifrice over 12 and 24 weeks.
This single-center, examiner-blinded, stratified, two-treatment arm, parallel-group analysis recruited adults suffering from moderate gingivitis. At baseline, after avoiding from tooth brushing overnight, the participants were assessed for the modified gingival index, bleeding index, and plaque index. The eligible participants, who fulfilled the inclusion/exclusion criteria, were stratified on the basis of gender and baseline mean modified gingival index score (low ≤2.00 /high > 2.00) and randomized to therapy.
After randomization, the participants underwent flossing and complete dental
prophylaxis. Following 12 and 24 weeks of twice-daily brushing with their
assigned therapy, the participants came back to the site (with overnight
plaque, avoided oral hygiene procedures for eight hours before the visit) for
the modified gingival index, bleeding index, and plaque index evaluations. The
therapeutic effect was determined by evaluating modified gingival index,
bleeding index, and plaque index scores. In total, 129 participants were
screened; 98 participants were randomized and 90 participants finished the
trial.
For all the outcome measures (modified gingival index, bleeding index, bleeding sites, and plaque index at weeks 12 and 24), substantial differences were noted between the therapies, in favor of stannous fluoride dentifrice compared to the negative control dentifrice, as shown in the following table:
At
24 weeks, 71% of subjects in the stannous fluoride therapy group displayed a level
of bleeding sites representative of clinical periodontal health (< 10%)
after dental prophylaxis and 24 weeks of the product usage.
Dentifrice
containing 0.454% weight/weight stannous fluoride can effectively manage
patients with gingivitis and supra-gingival plaque.
BMC Oral Health
Gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice: a 24-week randomized controlled trial
C R Parkinson et al.
Comments (0)